# Revvity, Inc. (RVTY) Investor Outlook: Analysts See 16.72% Upside Potential

- Link: https://www.directorstalkinterviews.com/revvity-inc-rvty-investor-outlook-analysts-see-16-72-upside-potential/4121209609
- Published: 2025-07-28T10:31:25+01:00
- Author: Madison Wilson

Revvity, Inc. (NYSE: RVTY), a prominent player in the healthcare sector, operates
within the diagnostics and research industry, offering a suite of health sciences
solutions. With a market capitalization of $12.22 billion, Revvity is a formidable
entity in the United States, providing cutting-edge technologies and services that
cater to a broad spectrum of needs, from early genetic disorder detection to innovative
genomic workflows.

Currently trading at $103.67, Revvity’s stock has shown resilience within the 52-
week range of $89.32 to $127.75. The modest price change of 0.02% underscores a 
period of relative stability as investors assess the company’s growth trajectory.
Notably, Revvity’s forward P/E ratio stands at 18.75, indicating investor confidence
in its future earnings potential, despite the absence of a trailing P/E ratio.

Revenue growth for Revvity is recorded at 2.30%, with an EPS of 2.42, reflecting
the company’s ability to generate earnings per share. Meanwhile, the return on equity
of 3.82% suggests a measured but steady return on shareholder investments. A significant
highlight for investors is the company’s free cash flow of over $743 million, which
provides a robust foundation for future investments and potential shareholder returns.

Dividend-seeking investors may find Revvity’s yield of 0.27% appealing, particularly
given its conservative payout ratio of 11.57%, which suggests ample room for dividend
growth. This aligns well with the company’s commitment to balancing reinvestment
in growth with returning value to shareholders.

Analyst sentiment towards Revvity is predominantly positive, with 12 buy ratings
and no sell ratings, alongside 6 hold ratings. The target price range is set between
$100.00 and $162.00, with an average target price of $121.00, indicating a potential
upside of 16.72% from the current trading price. This optimistic outlook is fueled
by Revvity’s strategic initiatives and robust product portfolio that address critical
needs in healthcare diagnostics and research.

From a technical analysis perspective, the stock’s 50-day moving average of $95.29
suggests short-term bullish momentum, while the 200-day moving average of $107.80
provides a broader lens on the stock’s performance. The RSI of 37.28 indicates the
stock is nearing oversold territory, potentially signaling a buying opportunity 
for contrarian investors. The MACD of 0.88, with a signal line at 0.54, further 
supports the positive momentum narrative.

Revvity’s comprehensive offerings, spanning life sciences and diagnostics, serve
a vast array of clients, including pharmaceutical and biotechnology companies, laboratories,
and public health authorities. This diverse customer base, coupled with the company’s
innovative product lines under renowned brands like AutoDELFIA and EUROIMMUN, positions
Revvity as a key player in advancing healthcare technologies.

As Revvity continues to evolve from its legacy as PerkinElmer, Inc., it leverages
decades of expertise since its founding in 1937. Headquartered in Waltham, Massachusetts,
the company’s strategic focus on health sciences solutions underscores its commitment
to addressing pressing healthcare challenges worldwide.

For investors seeking exposure to a company with a solid foundation in healthcare
innovation and promising growth prospects, Revvity presents a compelling opportunity.
With analyst ratings supporting potential upside and a strong operational base, 
Revvity stands poised to deliver value in the evolving landscape of healthcare diagnostics
and research.

Share on:
